Related Experiment Video
Updated: Jun 19, 2026
Murine Prostate Micro-dissection and Surgical Castration
Published on: May 11, 2016
Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in mice with genetic predisposition
Penghui Zhou1, Xianfeng Fang, Beth A McNally
1Division of Immunotherapy, Department of Surgery, University of Michigan School of Medicine and Cancer Center, Ann Arbor, MI 48109, USA.
Abstract:
The identification of individuals genetically susceptible to cancer calls for preventive measures to minimize the cancer risk in these high-risk populations. Immune prevention is made necessary by the anticipated health threat, but lack of enough high-affinity T cells against tumor-associated antigens and the unpredictability of tumor antigens make antigen-based immune prevention untenable for cancer. To address this issue, we explored a non-antigen-based cancer immune prevention strategy using the transgenic adenocarcinoma of mouse prostate model that spontaneously develops prostate cancer with 100% penetrance. We show that targeted mutation of the lymphotoxin alpha (LTalpha) gene efficiently rescued tumor-reactive T cells, drastically reduced cancer incidence, and almost completely ablated metastasis. Remarkably, short-term treatments with the fusion protein consisting of constant region of IgG and extracellular domain of lymphotoxin beta receptor (LTbetaRIg) interrupted clonal deletion, reduced the size of the primary cancer, and completely prevented metastasis later in life. Our data demonstrated the value of non-antigen-based immune prevention for those with a genetic predisposition to cancer.
Insights
Targeted gene mutation and novel protein treatments show promise for non-antigen-based cancer immune prevention in genetically susceptible individuals. These strategies rescued tumor-reactive T cells, reduced cancer incidence, and prevented metastasis.
Area of Science:
- Immunology
- Cancer Biology
- Genetics
Background:
- Genetic predisposition to cancer necessitates preventive strategies.
- Antigen-based immune prevention faces challenges due to T cell limitations and antigen unpredictability.
- Non-antigen-based approaches are needed for effective cancer immune prevention.
Purpose of the Study:
- To explore a non-antigen-based cancer immune prevention strategy.
- To investigate the role of lymphotoxin alpha (LTalpha) in cancer development and prevention.
- To evaluate the therapeutic potential of lymphotoxin beta receptor-Ig (LTbetaRIg) fusion protein.
Main Methods:
- Utilized the transgenic adenocarcinoma of mouse prostate model for spontaneous prostate cancer development.
- Performed targeted mutation of the lymphotoxin alpha (LTalpha) gene.
- Administered short-term treatments with the LTbetaRIg fusion protein.
Main Results:
- LTalpha gene mutation rescued tumor-reactive T cells, reduced cancer incidence, and inhibited metastasis.
- LTbetaRIg treatment interrupted clonal deletion, reduced primary tumor size, and prevented later-life metastasis.
- Demonstrated the efficacy of non-antigen-based immune prevention in a high-risk cancer model.
Conclusions:
- Non-antigen-based immune prevention is a viable strategy for individuals with genetic cancer predisposition.
- Targeting the lymphotoxin pathway offers a novel approach to cancer prevention.
- LTalpha modulation and LTbetaRIg therapy show significant potential in reducing cancer risk and metastasis.
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:16In-vitro Mutagenesis